GLP-1 medications like Semaglutide (found in Ozempic and Wegovy) and Tirzepatide (found in Mounjaro) mimic the body’s natural ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands Mounjaro and Zepbound, in India by 2025. The proposed dosages ranged from 2.5 ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...